BioRestorative Therapies, Inc.
BRTX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.00 | -0.03 | 0.04 |
| FCF Yield | -18.46% | -18.68% | -21.26% | -12.44% |
| EV / EBITDA | -3.95 | -2.84 | -4.00 | -5.67 |
| Quality | ||||
| ROIC | -68.22% | -78.24% | -31.53% | -22.79% |
| Gross Margin | 97.12% | 88.36% | 92.29% | 92.19% |
| Cash Conversion Ratio | 0.95 | 1.01 | 0.52 | 1.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 43.33% | 67.62% | 42.51% | 49.59% |
| Free Cash Flow Growth | 3.06% | -17.73% | -34.26% | 7.50% |
| Safety | ||||
| Net Debt / EBITDA | 0.47 | 0.26 | 0.21 | 0.65 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,284.22 | -18,457.61 | -12,629.16 | -1,916.59 |